What Xybion does

Xybion is a United States-based, life-sciences-focused software company founded in 1977 and headquartered in Princeton, NJ, that delivers cloud-based SaaS solutions for R&D, laboratory execution, and workforce health across pharmaceutical, biotechnology, contract research, and contract development and manufacturing organizations. Its product portfolio historically centered on Pristima, a preclinical study management system that handles data collection, analysis, and regulatory reporting for GLP-compliant studies, and was expanded in late 2023/October 2024 through the acquisition of Autoscribe Informatics, which added the configurable Matrix Gemini LIMS for laboratory data management. Together, these offerings target the regulated end of the drug R&D lifecycle, where GLP, SEND dataset, and FDA/EMA submission requirements shape buyer selection.

The business model is enterprise SaaS subscription-based, with pricing conducted on a quote basis, accompanied by a direct, demo-led sales motion targeting pharmaceutical, biotech, CRO, CDMO, and academic research buyers. GTM is reinforced by content marketing — white papers, on-demand webinars, case studies, industry events, and a 'Book a Demo' front door — and, since the July 2025 acquisition by Instem, Xybion's products are sold as part of Instem's broader life-sciences SaaS portfolio spanning in silico toxicology (Leadscope, Predict, KnowledgeScan, Centrus), study management (Climb, Provantis, Morphit, Pristima, BioRails, Logbook, NOTOCORD-hem), regulatory submission (SEND Advantage, eQCM, Submit, Compliance Builder), lab execution (Matrix Gemini LIMS), and clinical trial analytics (Accel, CTT Services, Aspire, Custom SCE, Blur). Distributed through multilingual web and field-sales channels, the combined platform addresses 700+ life-sciences clients globally.

Following the acquisition of all Xybion shares by Instem from Banerjee Group LLC — controlled by Dr. Pradip K. Banerjee, who served as Chairman & CEO — Xybion operates as a wholly-owned subsidiary, with its legacy Pristima and Matrix Gemini assets retained as product lines within Instem's Study Management and Lab Execution solution areas. The corporate trajectory has been one of inorganic expansion (Amadeus International in 2009, Autoscribe Informatics in 2023/2024) culminating in a change-of-control exit to a strategic acquirer in 2025.

Name

Xybion

Legal name

Xybion

Website

https://xybion.com

Company type

Private

Founded year

1977

Operating status

Acquired

Headcount range

101–250 employees

Short description

Xybion provides unified cloud-based SaaS for life sciences R&D, including preclinical study management (Pristima) and configurable Laboratory Information Management Systems (Matrix Gemini LIMS), serving pharmaceutical, biotechnology, CRO, CDMO, and academic research organizations. Founded in 1977 and now a wholly-owned subsidiary of Instem.

Ownership category

akta.pro rank

Product category

Life Sciences R&D Software (Preclinical Study & Laboratory Information Management)

NAICS

Software Publishers (513210)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

Quality, Compliance & Validation Software for Labs (GxP/CSV, eQMS for QC Labs) (HLAGAJAI)

akta.pro secondary industries

Regulatory Information Management (RIM) & Submission Publishing Software (HLAGAJAL), Biostatistics, Statistical Computing & Clinical Programming (SAS/R/Pipelines) (HLACAOAO), Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC)

Keywords

• Preclinical study management
• Laboratory information management
• Drug R&D software
• Regulatory submission software
• Life sciences SaaS

Headquarters

HQ city

Princeton

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. SaaS Subscription: Xybion operates as part of Instem's SaaS portfolio, delivering subscription-based software solutions for life sciences R&D. The revenue model centers on recurring SaaS subscriptions for study management, LIMS, regulatory submission, and clinical trial analytics platforms.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Xybion provides SaaS-based software solutions for life sciences R&D, including preclinical study management (Pristima) and configurable Laboratory Information Management Systems (Matrix Gemini LIMS, via the Autoscribe Informatics acquisition). The platforms support GLP-compliant data collection, analysis, SEND dataset preparation, and regulatory reporting, serving pharmaceutical, biotechnology, CRO, and CDMO organizations across the drug development pipeline.

Product overview

Xybion was a provider of laboratory and preclinical study management software. Its product portfolio included Pristima, a legacy study management software for preclinical research, and the company expanded its LIMS capabilities through the October 2024 acquisition of Autoscribe Informatics. Following Instem's July 2025 acquisition of all Xybion shares, the products are now integrated into Instem's SaaS portfolio under the Study Management and Lab Execution solution areas.

Differentiator

Problem solved

Functional benefit

Brands

• Pristima: Xybion Legacy study management software, now part of Instem's study management solutions.

Products and services

• Pristima Xybion legacy study management software for preclinical research that supports data collection, analysis, and regulatory reporting across in vivo studies. It is designed for pharmaceutical, biotechnology, and CRO research organizations needing GLP-compliant preclinical workflows.
• Matrix Gemini LIMS Configurable Laboratory Information Management System (LIMS) covering data collection, storage, and reporting while meeting global compliance and quality standards. Targeted at laboratory operations in life sciences, CROs, CDMOs, and academic research environments.

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Autoscribe InformaticscoreStrategic or Co-development Partner · 1 October 2024Xybion completed the acquisition of Autoscribe Informatics in October 2024 to expand its Laboratory Information Management System (LIMS) business. This strategic acquisition strengthens Xybion's LIMS portfolio and extends capabilities in laboratory data management, automation, and integration.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• LabWare: LabWare is a leading LIMS provider serving pharmaceutical, biotech, and CRO customers with configurable laboratory information management software. It is the most direct functional competitor to Xybion's Matrix Gemini and Pristima offerings in regulated preclinical environments.
• LabVantage Solutions: LabVantage provides a 100% web-based LIMS deployed across pharma, biotech, and CRO laboratories, directly competing with Xybion/Matrix Gemini for regulated lab data management workloads.
• STARLIMS (Abbott): STARLIMS, an Abbott-owned LIMS platform, targets laboratory data management in clinical, manufacturing, and life sciences research settings, overlapping directly with Xybion's LIMS footprint.
• Dotmatics: Dotmatics provides scientific informatics (ELN, LIMS, data management) for life sciences R&D, directly comparable to Xybion in unifying laboratory and study workflows for pharma and biotech.
• IDBS (Danaher): IDBS offers scientific data management and ELN platforms used by biotech and pharma for biologics and small-molecule R&D, overlapping with Xybion's study management and data harmonization capabilities.
• Core Informatics (Revvity Signals): Core Informatics, now part of Revvity's Signals software portfolio, delivers configurable LIMS and scientific data management for pharma and biotech, directly comparable to Xybion's Matrix Gemini value proposition.

Broad incumbents

• Thermo Fisher Scientific (SampleManager LIMS): Thermo Fisher's SampleManager LIMS is part of a broader life-sciences instrumentation and informatics portfolio, competing with Xybion for lab informatics deals while leveraging Thermo Fisher's scale and installed instruments.
• Veeva Systems: Veeva's Vault platform spans clinical, regulatory, quality, and lab data management for life sciences, providing a broader alternative to Xybion/Instem's preclinical-to-clinical stack.
• Agilent Technologies (OpenLab): Agilent's OpenLab informatics suite includes LIMS and chromatography data systems used in regulated laboratories, overlapping with Xybion's lab execution and compliance positioning.

Emerging players

• Benchling: Benchling offers a cloud-native R&D platform covering biological data, registries, and lab execution, increasingly competing with Xybion for biotech and pharma digital lab transformations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/xybion
• Facebookfacebook.com/xybion
• LinkedInlinkedin.com/company/xybion-corporation

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xybion